Agbonesa, Mark Jay T.
HRN: 21-32-49 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/10/2022
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
05/10/2022
05/16/2022
IV
350
Q6 For 7 Days
For Pneumonia
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes